A recent panel discussion highlighted the evolving landscape of epinephrine delivery methods, aiming to improve treatment outcomes for anaphylaxis. Experts reviewed current options and emerging alternatives, focusing on how these advancements can reduce barriers to the timely administration of epinephrine, a critical medication for life-threatening allergic reactions.
The panel began by examining the variety of injectable epinephrine products available. In the United States, autoinjectors come in doses of 0.1 mg, 0.15 mg, and 0.3 mg, while a 0.5 mg autoinjector is available in Europe. Dr. David Golden of Johns Hopkins University raised concerns about the potential for underdosing in larger adults, emphasizing the need for a second 0.3 mg dose if symptoms do not improve. He noted that using a weight-based dosing approach, a 0.3 mg dose is suitable for individuals weighing approximately 30 kg (66 pounds), which highlights the necessity for repeated dosing in adolescents and adults experiencing severe allergic reactions.
Despite the advantages of autoinjectors, experts highlighted that many issues related to anaphylaxis outcomes are not solely pharmacological. Human factors such as fear of needles, reluctance to carry devices, uncertainty about diagnosis, and hesitation to use epinephrine early are significant barriers.
Emerging Non-Injectable Options
The discussion then shifted to newly approved and emerging non-injectable delivery methods. Dr. Golden discussed the first FDA-approved intranasal epinephrine spray, known as Neffy, which has been available for over a year. This product’s approval was based on pharmacokinetic data demonstrating that plasma epinephrine levels are comparable to existing intramuscular options. Early real-world experiences have shown promising results, positioning the nasal spray as a viable alternative that falls between manual intramuscular injection and autoinjectors in terms of efficacy.
The panel also explored additional products in development, including other nasal formulations and a sublingual oral film called Anaphylm. This innovative approach uses a prodrug method to address the challenges associated with epinephrine absorption. Dr. Jay Lieberman from the University of Tennessee Health Science Center noted that many patients express a preference for oral medications, making a sublingual option particularly attractive if it proves effective.
Newer formulations may not only improve accessibility but also offer practical benefits such as longer shelf life and enhanced temperature stability, which could further encourage their use in emergency situations.
Call for Early Action and Education
Concluding the discussion, Dr. Golden and Dr. Lieberman reiterated the central message of the panel: improving anaphylaxis outcomes necessitates earlier use of epinephrine and reducing barriers to its administration. They emphasized the need to move away from outdated reliance on antihistamines and corticosteroids during acute care situations.
As Dr. Lieberman succinctly articulated, “Epinephrine, epinephrine. Let’s stop using steroids for anaphylaxis, and let’s use epinephrine early on and get rid of barriers to use.”
The insights shared by these experts shed light on the urgent need for enhanced education and resources to ensure that patients and caregivers can respond promptly and effectively to anaphylactic emergencies. The ongoing innovations in epinephrine delivery systems hold promise for a future where timely treatment becomes the standard, ultimately saving lives in critical moments.
